Cure My Disease

Don't miss your cure!

 Log in / Sign up

400 patients studied to uncover clues about neovascular glaucoma

NCT ID NCT07177807

Knowledge-focused Sponsor: Zhongnan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked back at the medical records of 400 people with neovascular glaucoma, a severe eye condition. Researchers wanted to see how it relates to other diseases, lifestyle factors, and inflammation. The goal is to better understand the condition and guide future treatment choices.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

400 people

The number who actually took part.

Started

Jan 2018

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with NVG diagnosed by ophthalmic examination in the Second Clinical Hospital of Wuhan University, Central Hospital of Enshi Tujia and Miao Autonomous Prefecturefrom and Central Hospital of Xiaogan from January 2018 to September 2024 were enrolled. A certain number of healthy volunteers in the Physical Examination Center of the Second Clinical Hospital of Wuhan University from January 2018 to September 2024 were enrolled

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who met the diagnostic criteria for NVG. Exclusion Criteria: * Patients with incomplete clinical data and information. * Severe systemic diseases (such as chronic renal failure requiring dialysis, severe neurological diseases, immune diseases), pregnancy or lactation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neovascular glaucoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic retinopathy neovascular glaucoma retinal vein occlusion

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neovascular glaucoma

Contacts and locations

Locations

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, 430071, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.